


**What is claimed is:**

1. A compound of Formula (I):



(I)

or a stereoisomer or pharmaceutically acceptable salt form thereof, wherein:

A is -C(O)NHOH, -C(O)NHOR<sup>5</sup>, -C(O)NHOR<sup>6</sup>, -N(OH)COR<sup>5</sup>, or -N(OH)CHO;

U is absent or is O, NR<sup>a1</sup>, C(O), CR<sup>a</sup>(OH), C(O)O, OC(O), C(O)NR<sup>a1</sup>, NR<sup>a1</sup>C(O),  
 5 OC(O)O, OC(O)NR<sup>a1</sup>, NR<sup>a1</sup>C(O)O, NR<sup>a1</sup>C(O)NR<sup>a1</sup>, S(O)<sub>p</sub>, S(O)<sub>p</sub>NR<sup>a1</sup>, NR<sup>a1</sup>S(O)<sub>p</sub>, or  
 NR<sup>a1</sup>SO<sub>2</sub>NR<sup>a1</sup>;

X is absent or is C<sub>1-10</sub> alkylene, C<sub>2-10</sub> alkenylene, or C<sub>2-10</sub> alkynylene;

Y is absent or is O, NR<sup>a1</sup>, S(O)<sub>p</sub>, or C(O);

provided that U-X-Y form a linker of at least two atoms between Z and Z<sup>a</sup> and is  
 10 other than OC(O) or OC(O)alkylene;

Z is phenyl substituted with 0-1 R<sup>b</sup>, naphthyl substituted with 0-1 R<sup>b</sup>, pyridyl  
 substituted with 0-1 R<sup>b</sup>, or pyrimidyl substituted with 0-1 R<sup>b</sup>;

Z<sup>a</sup> is a C<sub>3-13</sub> carbocycle substituted with 1-5 R<sup>c</sup> or a 5-14 membered heterocycle  
 consisting of carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)<sub>p</sub>, and  
 15 substituted with 1-5 R<sup>c</sup>, provided that if Z<sup>a</sup> is bicyclic, it does not contain a bridging nitrogen  
 atom;

provided that U, Y, Z, and Z<sup>a</sup> do not combine to form a N-N, N-O, O-N, O-O,  
 S(O)<sub>p</sub>-O, O-S(O)<sub>p</sub>, or S(O)<sub>p</sub>-S(O)<sub>p</sub> group;

R<sup>1</sup> is Q, C<sub>1-6</sub> alkylene-Q, C<sub>2-6</sub> alkenylene-Q, C<sub>2-6</sub> alkynylene-Q,  
 20 -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>O(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>NR<sup>a</sup>(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>C(O)(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q,  
 -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>C(O)O(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>OC(O)(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>C(O)NR<sup>a</sup>R<sup>a1</sup>,  
 -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>C(O)NR<sup>a</sup>(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>NR<sup>a</sup>C(O)(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q,  
 -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>OC(O)O(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>OC(O)NR<sup>a</sup>(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q,  
 -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>NR<sup>a</sup>C(O)O(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>NR<sup>a</sup>C(O)NR<sup>a</sup>(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q,  
 25 -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>S(O)<sub>p</sub>(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>SO<sub>2</sub>NR<sup>a</sup>(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q,  
 -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>NR<sup>a</sup>SO<sub>2</sub>(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q, or (CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>NR<sup>a</sup>SO<sub>2</sub>NR<sup>a</sup>(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q;

$R^2$  is  $Q^1$ ,  $C_{1-6}$  alkylene- $Q^1$ ,  $C_{2-6}$  alkenylene- $Q^1$ ,  $C_{2-6}$  alkynylene- $Q^1$ ,  
 $-(CR^aRa^1)_rO(CR^aRa^1)_s-Q^1$ ,  $-(CR^aRa^1)_rNR^a(CR^aRa^1)_s-Q^1$ ,  $-(CR^aRa^1)_rC(O)(CR^aRa^1)_s-Q^1$ ,  
 $-(CR^aRa^1)_rC(O)O(CR^aRa^1)_s-Q^1$ ,  $-(CR^aRa^1)_rOC(O)(CR^aRa^1)_s-Q^1$ ,  $-(CR^aRa^1)_rC(O)NR^aRa^1$ ,  
 $-(CR^aRa^1)_rC(O)NR^a(CR^aRa^1)_s-Q^1$ ,  $-(CR^aRa^1)_rNR^aC(O)(CR^aRa^1)_s-Q^1$ ,  
 5  $-(CR^aRa^1)_rOC(O)O(CR^aRa^1)_s-Q^1$ ,  $-(CR^aRa^1)_rOC(O)NR^a(CR^aRa^1)_s-Q^1$ ,  
 $-(CR^aRa^1)_rNR^aC(O)NR^a(CR^aRa^1)_s-Q^1$ ,  $-(CR^aRa^1)_2rS(O)_p(CR^aRa^1)_s-Q^1$ ,  
 $-(CR^aRa^1)_rSO_2NR^a(CR^aRa^1)_s-Q^1$ ,  $-(CR^aRa^1)_rNR^aSO_2(CR^aRa^1)_s-Q^1$ , or  
 $-(CR^aRa^1)_rNR^aSO_2NR^a(CR^aRa^1)_s-Q^1$ ;

provided that when  $n$  is 0 and  $CR^1R^2$  is  $CHNH_2$ , then  $Z^a$  is other than unsubstituted  
 10 phenyl;

$Q$  is, independently at each occurrence, H,  $CHF_2$ ,  $CH_2F$ ,  $CF_3$ , a  $C_{3-13}$  carbocycle  
 substituted with 0-5  $R^d$ , or a 5-14 membered heterocycle consisting of carbon atoms and 1-4  
 heteroatoms selected from N, O, and  $S(O)_p$ , and substituted with 0-5  $R^d$ ;

$Q^1$  is, independently at each occurrence, H, a  $C_{3-13}$  carbocycle substituted with 0-5  
 15  $R^d$ , or a 5-14 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms  
 selected from N, O, and  $S(O)_p$ , and substituted with 0-5  $R^d$ ;

alternatively,  $R^1$  and  $R^2$ , when attached to the same carbon atom, combine to form a  
 3-7 membered carbocyclic or heterocyclic ring consisting of: carbon atoms and 0-3  
 heteroatoms selected from the group consisting of N, O, and  $S(O)_p$  and substituted with 0-2  
 20  $R^d$ ;

alternatively, when two  $R^1$  groups are present they and the two carbon atoms to  
 which they are attached combine to form a 4-7 membered carbocyclic or heterocyclic ring  
 consisting of: carbon atoms and 0-3 heteroatoms selected from the group consisting of N, O,  
 and  $S(O)_p$  and substituted with 0-2  $R^d$ , provided that when  $R^1$ s combine to form a ring  $Z$  is  
 25 other than naphthylene;

$R^3$  is H or  $C_{1-6}$  alkyl;

$R^4$  is H,  $C_{1-6}$  alkyl, phenyl, or benzyl;

provided that when  $R^4$  is other than H and  $n$  is 0, then one or both of  $R^1$  and  $R^2$  are  
 other than H;

alternatively, R<sup>3</sup> and R<sup>4</sup> together with the carbon and oxygen atoms to which they are attached form a 5-6 membered ring consisting of, in addition to the carbon and oxygen atom shown, carbon atoms and 0-1 ring double bonds and substituted with 0-2 R<sup>c</sup>;

R<sup>a</sup> is, independently at each occurrence, H, C<sub>1-6</sub> alkyl, phenyl, or benzyl;

5 R<sup>a1</sup> is, independently at each occurrence, H, C<sub>1-6</sub> alkyl substituted with 0-1 R<sup>c1</sup>, C<sub>2-6</sub> alkenyl substituted with 0-1 R<sup>c1</sup>, C<sub>2-6</sub> alkynyl substituted with 0-1 R<sup>c1</sup>, or -(CH<sub>2</sub>)<sub>r</sub>-3-8 membered carbocyclic or heterocyclic ring consisting of carbon atoms and 0-2 ring heteroatoms selected from N, NR<sup>a2</sup>, O, and S(O)<sub>p</sub>, and substituted with 0-3 R<sup>c1</sup>;

alternatively, R<sup>a</sup> and R<sup>a1</sup> when attached to a nitrogen, together with the nitrogen to  
10 which they are attached, combine to form a 5 or 6 membered heterocycle consisting of carbon atoms and from 0-1 additional heteroatoms selected from N, NR<sup>a2</sup>, O, and S(O)<sub>p</sub>;

R<sup>a2</sup> is, independently at each occurrence, C<sub>1-4</sub> alkyl, phenyl, or benzyl;

R<sup>a3</sup> is, independently at each occurrence, H, C<sub>1-6</sub> alkyl substituted with 0-1 R<sup>c1</sup>, C<sub>2-6</sub> alkenyl substituted with 0-1 R<sup>c1</sup>, C<sub>2-6</sub> alkynyl substituted with 0-1 R<sup>c1</sup>, or  
15 -(CH<sub>2</sub>)<sub>r</sub>-3-8 membered carbocyclic or heterocyclic ring consisting of carbon atoms and 0-2 ring heteroatoms selected from N, NR<sup>a2</sup>, O, and S(O)<sub>p</sub>, and substituted with 0-3 R<sup>c1</sup>;

R<sup>b</sup> is, independently at each occurrence, C<sub>1-6</sub> alkyl substituted with 0-1 R<sup>c1</sup>, OR<sup>a</sup>, SR<sup>a</sup>, Cl, F, Br, I, =O, CN, NO<sub>2</sub>, -NR<sup>a</sup>R<sup>a1</sup>, -C(O)R<sup>a</sup>, -C(O)OR<sup>a</sup>, -C(O)NR<sup>a</sup>R<sup>a1</sup>,  
-C(S)NR<sup>a</sup>R<sup>a1</sup>, -NR<sup>a</sup>C(O)NR<sup>a</sup>R<sup>a1</sup>, -OC(O)NR<sup>a</sup>R<sup>a1</sup>, -NR<sup>a</sup>C(O)OR<sup>a</sup>, -S(O)<sub>2</sub>NR<sup>a</sup>R<sup>a1</sup>,  
20 -NR<sup>a</sup>S(O)<sub>2</sub>R<sup>a3</sup>, -NR<sup>a</sup>S(O)<sub>2</sub>NR<sup>a</sup>R<sup>a1</sup>, -OS(O)<sub>2</sub>NR<sup>a</sup>R<sup>a1</sup>, -S(O)<sub>p</sub>R<sup>a3</sup>, CF<sub>3</sub>, CF<sub>2</sub>CF<sub>3</sub>, CHF<sub>2</sub>, CH<sub>2</sub>F, or phenyl;

R<sup>c</sup> is, independently at each occurrence, H, OR<sup>a</sup>, Cl, F, Br, I, =O, CN, NO<sub>2</sub>, CF<sub>3</sub>, -CF<sub>2</sub>CF<sub>3</sub>, CH<sub>2</sub>F, CHF<sub>2</sub>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>NR<sup>a</sup>R<sup>a1</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>C(=NCN)NR<sup>a</sup>R<sup>a1</sup>,  
-(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>C(=NR<sup>a</sup>)NR<sup>a</sup>R<sup>a1</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>C(=NOR<sup>a</sup>)NR<sup>a</sup>R<sup>a1</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>C(O)NR<sup>a</sup>OH,  
25 -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>C(O)R<sup>a1</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>C(O)OR<sup>a1</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>C(S)OR<sup>a1</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>C(O)NR<sup>a</sup>R<sup>a1</sup>,  
-(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>NR<sup>a</sup>C(O)R<sup>a1</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>C(S)NR<sup>a</sup>R<sup>a1</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>OC(O)NR<sup>a</sup>R<sup>a1</sup>,  
-(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>NR<sup>a</sup>C(O)OR<sup>a1</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>NR<sup>a</sup>C(O)NR<sup>a</sup>R<sup>a1</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>S(O)<sub>p</sub>R<sup>a3</sup>,  
-(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>SO<sub>2</sub>NR<sup>a</sup>R<sup>a1</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>NR<sup>a</sup>SO<sub>2</sub>R<sup>a3</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>NR<sup>a</sup>SO<sub>2</sub>NR<sup>a</sup>R<sup>a1</sup>, C<sub>1-6</sub> alkyl  
substituted with 0-2 R<sup>c1</sup>, C<sub>2-6</sub> alkenyl substituted with 0-2 R<sup>c1</sup>, C<sub>2-6</sub> alkynyl substituted with  
30 0-2 R<sup>c1</sup>, (CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>-C<sub>3-10</sub> carbocycle substituted with 0-2 R<sup>c1</sup>, or (CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>-5-14 membered

heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)<sub>p</sub>, and substituted with 0-2 R<sup>c1</sup>;

alternatively, when two R<sup>c</sup> groups are attached to the same carbon atom, they form a 3-8 membered carbocyclic or heterocyclic spiro ring C substituted with 0-2 R<sup>c1</sup> and consisting of carbon atoms, 0-4 ring heteroatoms selected from O, N, and S(O)<sub>p</sub>, and 0-2 double bonds, provided that ring C contains other than a S-S, O-O, or S-O bond;

alternatively, when two R<sup>c</sup> groups are attached to adjacent carbon atoms, together with the carbon atoms to which they are attached they form a 5-7 membered carbocyclic or heterocyclic ring D substituted with 0-2 R<sup>c1</sup> and consisting of: carbon atoms and 0-2 heteroatoms selected from N, O, and S(O)<sub>p</sub>;

R<sup>c1</sup> is, independently at each occurrence, H, C<sub>1-4</sub> alkyl, OR<sup>a</sup>, Cl, F, Br, I, =O, CF<sub>3</sub>, CN, NO<sub>2</sub>, -C(O)R<sup>a</sup>, -C(O)OR<sup>a</sup>, -C(O)NR<sup>a</sup>R<sup>a</sup>, or -S(O)<sub>p</sub>R<sup>a</sup>;

R<sup>d</sup> is, independently at each occurrence, C<sub>1-6</sub> alkyl, OR<sup>a</sup>, Cl, F, Br, I, =O, CN, NO<sub>2</sub>, NR<sup>a</sup>R<sup>a1</sup>, C(O)R<sup>a</sup>, C(O)OR<sup>a</sup>, C(O)NR<sup>a</sup>R<sup>a1</sup>, C(S)NR<sup>a</sup>R<sup>a1</sup>, R<sup>a</sup>NC(O)NR<sup>a</sup>R<sup>a1</sup>, OC(O)NR<sup>a</sup>R<sup>a1</sup>, R<sup>a</sup>NC(O)O, S(O)<sub>2</sub>NR<sup>a</sup>R<sup>a1</sup>, NR<sup>a</sup>S(O)<sub>2</sub>R<sup>a3</sup>, NR<sup>a</sup>S(O)<sub>2</sub>NR<sup>a</sup>R<sup>a1</sup>, OS(O)<sub>2</sub>NR<sup>a</sup>R<sup>a1</sup>, S(O)<sub>p</sub>R<sup>a3</sup>, CF<sub>3</sub>, CF<sub>2</sub>CF<sub>3</sub>, C<sub>3-10</sub> carbocycle, or a 5-14 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)<sub>p</sub>;

R<sup>5</sup> is, independently at each occurrence, C<sub>1-10</sub> alkyl substituted with 0-2 R<sup>b</sup>, or C<sub>1-8</sub> alkyl substituted with 0-2 R<sup>e</sup>;

R<sup>e</sup> is, independently at each occurrence, phenyl substituted with 0-2 R<sup>b</sup>, or biphenyl substituted with 0-2 R<sup>b</sup>;

R<sup>6</sup> is, independently at each occurrence, phenyl, naphthyl, C<sub>1-10</sub> alkyl-phenyl-C<sub>1-6</sub> alkyl-, C<sub>3-11</sub> cycloalkyl, C<sub>1-6</sub> alkylcarbonyloxy-C<sub>1-3</sub> alkyl-, C<sub>1-6</sub> alkoxy carbonyloxy-C<sub>1-3</sub> alkyl-, C<sub>2-10</sub> alkoxy carbonyl, C<sub>3-6</sub> cycloalkylcarbonyloxy-C<sub>1-3</sub> alkyl-, C<sub>3-6</sub> cycloalkoxy carbonyloxy-C<sub>1-3</sub> alkyl-, C<sub>3-6</sub> cycloalkoxy carbonyl, phenoxycarbonyl, phenyloxy carbonyloxy-C<sub>1-3</sub> alkyl-, phenylcarbonyloxy-C<sub>1-3</sub> alkyl-, C<sub>1-6</sub> alkoxy-C<sub>1-6</sub> alkylcarbonyloxy-C<sub>1-3</sub> alkyl-, [5-(C<sub>1</sub>-C<sub>5</sub> alkyl)-1,3-dioxa-cyclopenten-2-one-yl]methyl, [5-(R<sup>a</sup>)-1,3-dioxa-cyclopenten-2-one-yl]methyl, (5-aryl-1,3-dioxa-cyclopenten-2-one-yl)methyl, -C<sub>1-10</sub> alkyl-NR<sup>7</sup>R<sup>7a</sup>, -CH(R<sup>8</sup>)OC(=O)R<sup>9</sup>, or -CH(R<sup>8</sup>)OC(=O)OR<sup>9</sup>;

R<sup>7</sup> is H, C<sub>1-10</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>3-6</sub> cycloalkyl-C<sub>1-3</sub> alkyl-, or phenyl-C<sub>1-6</sub> alkyl-;

R<sup>7a</sup> is H, C<sub>1-10</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>3-6</sub> cycloalkyl-C<sub>1-3</sub> alkyl-, or phenyl-C<sub>1-6</sub> alkyl-;

R<sup>8</sup> is H or C<sub>1-4</sub> linear alkyl;

5 R<sup>9</sup> is H, C<sub>1-8</sub> alkyl substituted with 1-2 R<sup>f</sup>, C<sub>3-8</sub> cycloalkyl substituted with 1-2 R<sup>f</sup>, or phenyl substituted with 0-2 R<sup>b</sup>;

R<sup>f</sup> is, independently at each occurrence, C<sub>1-4</sub> alkyl, C<sub>3-8</sub> cycloalkyl, C<sub>1-5</sub> alkoxy, or phenyl substituted with 0-2 R<sup>b</sup>;

n is 0 or 1;

10 p, at each occurrence, is selected from 0, 1, and 2;

r, at each occurrence, is selected from 0, 1, 2, 3, and 4; and

s, at each occurrence, is selected from 0, 1, 2, 3, and 4;

provided that:

(a) when R<sup>4</sup>, R<sup>1</sup>, and R<sup>2</sup> are all H, then Z<sup>a</sup> is other than a benzo-fused 5-6 membered  
15 heterocycle attached at the 2- or 3-position of the 5-6 membered heterocycle; and

(b) when Z<sup>a</sup> is a benzo-fused 5-6 membered heterocycle attached at the 2- or 3-position of the 5-6 membered heterocycle, then at least one of R<sup>1</sup>, R<sup>2</sup>, and R<sup>4</sup> is other than H.

2. A compound according to Claim 1, wherein:

20 U is absent or is O, NR<sup>a1</sup>, C(O), CR<sup>a</sup>(OH), C(O)O, OC(O), C(O)NR<sup>a1</sup>, NR<sup>a1</sup>C(O), S(O)<sub>p</sub>, S(O)<sub>p</sub>NR<sup>a1</sup>, or NR<sup>a1</sup>S(O)<sub>p</sub>;

X is absent or is C<sub>1-3</sub> alkylene or C<sub>3-4</sub> alkynylene;

Y is absent or is O, NR<sup>a1</sup>, S(O)<sub>p</sub>, or C(O);

25 provided that U-X-Y form a linker of at least two atoms between Z and Z<sup>a</sup> and is other than OC(O) or OC(O)alkylene;

Z is phenyl substituted with 0-1 R<sup>b</sup>, naphthyl substituted with 0-1 R<sup>b</sup>, or pyridyl substituted with 0-1 R<sup>b</sup>;

30 Z<sup>a</sup> is a C<sub>3-13</sub> carbocycle substituted with 1-3 R<sup>c</sup> or a 5-14 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)<sub>p</sub>, and substituted with 1-3 R<sup>c</sup>, provided that if Z<sup>a</sup> is bicyclic, it does not contain a bridging nitrogen atom;

provided that U, Y, Z, and Z<sup>a</sup> do not combine to form a N-N, N-O, O-N, O-O, S(O)<sub>p</sub>-O, O-S(O)<sub>p</sub>, or S(O)<sub>p</sub>-S(O)<sub>p</sub> group;

R<sup>1</sup> is Q, C<sub>1-6</sub> alkylene-Q, C<sub>2-6</sub> alkenylene-Q, C<sub>2-6</sub> alkynylene-Q,  
 -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>O(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>NR<sup>a</sup>(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>C(O)(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q,  
 5 -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>C(O)O(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>C(O)NR<sup>a</sup>R<sup>a1</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>C(O)NR<sup>a</sup>(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q,  
 -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>S(O)<sub>p</sub>(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>SO<sub>2</sub>NR<sup>a</sup>(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q, or  
 -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>NR<sup>a</sup>SO<sub>2</sub>(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q;

R<sup>2</sup> is Q<sup>1</sup>, C<sub>1-6</sub> alkylene-Q<sup>1</sup>, C<sub>2-6</sub> alkenylene-Q<sup>1</sup>, C<sub>2-6</sub> alkynylene-Q<sup>1</sup>,  
 -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>O(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q<sup>1</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>NR<sup>a</sup>(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q<sup>1</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>C(O)(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q<sup>1</sup>,  
 10 -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>C(O)O(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q<sup>1</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>OC(O)(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q<sup>1</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>C(O)NR<sup>a</sup>R<sup>a1</sup>,  
 -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>C(O)NR<sup>a</sup>(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q<sup>1</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>NR<sup>a</sup>C(O)(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q<sup>1</sup>,  
 -(CR<sup>a</sup>R<sup>a1</sup>)<sub>2</sub>S(O)<sub>p</sub>(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q<sup>1</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>SO<sub>2</sub>NR<sup>a</sup>(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q<sup>1</sup>, or  
 -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>NR<sup>a</sup>SO<sub>2</sub>(CR<sup>a</sup>R<sup>a1</sup>)<sub>s</sub>-Q<sup>1</sup>;

provided that when n is 0 and CR<sup>1</sup>R<sup>2</sup> is CHNH<sub>2</sub>, then Z<sup>a</sup> is other than unsubstituted  
 15 phenyl;

Q is, independently at each occurrence, H, CHF<sub>2</sub>, CH<sub>2</sub>F, CF<sub>3</sub>, a C<sub>3-13</sub> carbocycle substituted with 0-3 R<sup>d</sup>, or a 5-14 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)<sub>p</sub>, and substituted with 0-3 R<sup>d</sup>;

alternatively, R<sup>1</sup> and R<sup>2</sup>, when attached to the same carbon atom, combine to form a  
 20 5-6 membered carbocyclic or heterocyclic ring consisting of: carbon atoms and 0-3 heteroatoms selected from the group consisting of N, O, and S(O)<sub>p</sub> and substituted with 0-2 R<sup>d</sup>;

R<sup>a</sup> is, independently at each occurrence, H, C<sub>1-6</sub> alkyl, phenyl, or benzyl;

R<sup>a1</sup> is, independently at each occurrence, H, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl,  
 25 C<sub>2-6</sub> alkynyl, or -(CH<sub>2</sub>)<sub>r</sub>-3-8 membered carbocyclic or heterocyclic ring consisting of carbon atoms and 0-2 ring heteroatoms selected from N, NR<sup>a2</sup>, O, and S(O)<sub>p</sub>;

alternatively, R<sup>a</sup> and R<sup>a1</sup> when attached to a nitrogen, together with the nitrogen to which they are attached, combine to form a 5 or 6 membered heterocycle consisting of carbon atoms and from 0-1 additional heteroatoms selected from N, NR<sup>a2</sup>, O, and S(O)<sub>p</sub>;

$R^c$  is, independently at each occurrence, H,  $OR^a$ , Cl, F, Br, =O, CN,  $NO_2$ ,  $CF_3$ ,  $CH_2F$ ,  $CHF_2$ ,  $CF_2CF_3$ ,  $-(CR^aR^{a1})_rNR^aR^{a1}$ ,  $-(CR^aR^{a1})_rC(O)R^{a1}$ ,  $-(CR^aR^{a1})_rC(O)OR^{a1}$ ,  $-(CR^aR^{a1})_rC(O)NR^aR^{a1}$ ,  $-(CR^aR^{a1})_rNR^aC(O)R^{a1}$ ,  $-(CR^aR^{a1})_rS(O)_pR^{a3}$ ,  $-(CR^aR^{a1})_rSO_2NR^aR^{a1}$ ,  $-(CR^aR^{a1})_rNR^aSO_2R^{a3}$ ,  $C_{1-6}$  alkyl substituted with 0-1  $R^{c1}$ ,

- 5  $C_{2-6}$  alkenyl substituted with 0-1  $R^{c1}$ ,  $C_{2-6}$  alkynyl substituted with 0-1  $R^{c1}$ ,  $-(CH_2)_r-C_{3-6}$  carbocycle substituted with 0-2  $R^{c1}$ , or  $-(CH_2)_r-5-6$  membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from N, O, and  $S(O)_p$ , and substituted with 0-2  $R^{c1}$ ;

- alternatively, when two  $R^c$  groups are attached to the same carbon atom, they form a  
10 3-8 membered carbocyclic or heterocyclic spiro ring C substituted with 0-2  $R^{c1}$  and consisting of carbon atoms, 0-4 ring heteroatoms selected from O, N, and  $S(O)_p$ , and 0-2 double bonds, provided that ring C contains other than a S-S, O-O, or S-O bond;

- alternatively, when two  $R^c$  groups are attached to adjacent carbon atoms, together with the carbon atoms to which they are attached they form a 5-7 membered carbocyclic or  
15 heterocyclic ring D substituted with 0-2  $R^{c1}$  and consisting of: carbon atoms and 0-2 heteroatoms selected from N, O, and  $S(O)_p$ ;

- $R^d$  is, independently at each occurrence,  $C_{1-6}$  alkyl,  $OR^a$ , Cl, F, Br, =O, CN,  $NO_2$ ,  $-NR^aR^{a1}$ ,  $-C(O)R^a$ ,  $-C(O)OR^a$ ,  $-C(O)NR^aR^{a1}$ ,  $-S(O)_2NR^aR^{a1}$ ,  $-NR^aS(O)_2R^{a3}$ ,  $-S(O)_pR^{a3}$ ,  $CF_3$ ,  $C_{3-6}$  carbocycle, or a 5-6 membered heterocycle consisting of carbon atoms and 1-4  
20 heteroatoms selected from N, O, and  $S(O)_p$ ;

$R^5$  is, independently at each occurrence,  $C_{1-6}$  alkyl substituted with 0-2  $R^b$ , or  $C_{1-4}$  alkyl substituted with 0-2  $R^e$ ;

$R^7$  is H,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{3-6}$  cycloalkyl- $C_{1-3}$  alkyl-, or phenyl- $C_{1-6}$  alkyl-;

$R^{7a}$  is H,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{3-6}$  cycloalkyl- $C_{1-3}$  alkyl-, or phenyl- $C_{1-6}$  alkyl-;

- 25  $R^9$  is H,  $C_{1-6}$  alkyl substituted with 1-2  $R^f$ ,  $C_{3-6}$  cycloalkyl substituted with 1-2  $R^f$ , or phenyl substituted with 0-2  $R^b$ ; and

$R^f$  is, independently at each occurrence,  $C_{1-4}$  alkyl,  $C_{3-6}$  cycloalkyl,  $C_{1-5}$  alkoxy, or phenyl substituted with 0-2  $R^b$ ;

provided that:

- 30 (a) when  $R^4$ ,  $R^1$ , and  $R^2$  are all H, then  $Z^a$  is other than a benzo-fused 5-6 membered heterocycle attached at the 2- or 3-position of the 5-6 membered heterocycle; and

(b) when  $Z^a$  is a benzo-fused 5-6 membered heterocycle attached at the 2- or 3-position of the 5-6 membered heterocycle, then at least one of  $R^1$ ,  $R^2$ , and  $R^4$  is other than H.

3. A compound according to Claim 2, wherein:

5 A is  $-C(O)NHOH$  or  $-N(OH)CHO$ ;

U is absent or is O,  $NR^{a1}$ ,  $C(O)$ ,  $CR^a(OH)$ ,  $C(O)NR^{a1}$ ,  $NR^{a1}C(O)$ ,  $S(O)_p$ ,  $S(O)_pNR^{a1}$ , or  $NR^{a1}S(O)_p$ ;

X is absent or is methylene, ethylene, propynylene, or butynylene;

provided that U-X-Y form a linker of at least two atoms between Z and  $Z^a$ ;

10  $Z^a$  is a  $C_{5-10}$  carbocycle substituted with 1-3  $R^c$ , or a 5-10 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from N, O, and  $S(O)_p$ , and substituted with 1-3  $R^c$ , provided that if  $Z^a$  is bicyclic, it does not contain a bridging nitrogen atom;

provided that U, Y, Z, and  $Z^a$  do not combine to form a N-N, N-O, O-N, O-O,

15  $S(O)_p$ -O, O- $S(O)_p$ , or  $S(O)_p$ - $S(O)_p$  group;

$R^1$  is Q,  $C_{1-6}$  alkylene-Q,  $C_{2-6}$  alkenylene-Q,  $C_{2-6}$  alkynylene-Q,  $-(CH_2)_rO(CH_2)_s-Q$ ,  $-(CH_2)_rNR^a(CH_2)_s-Q$ ,  $-(CH_2)_rC(O)(CH_2)_s-Q$ ,  $-(CH_2)_rC(O)O(CH_2)_s-Q$ ,  $-(CH_2)_rC(O)NR^aR^{a1}$ ,  $-(CH_2)_rC(O)NR^a(CH_2)_s-Q$ ,  $-(CH_2)_rNR^aC(O)(CH_2)_s-Q$ ,  $-(CH_2)_rS(O)_p(CH_2)_s-Q$ ,  $-(CH_2)_rSO_2NR^a(CH_2)_s-Q$ , or  $-(CH_2)_rNR^aSO_2(CH_2)_s-Q$ ;

20  $R^2$  is  $Q^1$ ,  $C_{1-6}$  alkylene- $Q^1$ ,  $C_{2-6}$  alkenylene- $Q^1$ ,  $C_{2-6}$  alkynylene- $Q^1$ ,  $-(CR^aR^{a1})_rO(CR^aR^{a1})_s-Q^1$ ,  $-(CR^aR^{a1})_rNR^a(CR^aR^{a1})_s-Q^1$ ,  $-(CR^aR^{a1})_rC(O)(CR^aR^{a1})_s-Q^1$ ,  $-(CR^aR^{a1})_rC(O)O(CR^aR^{a1})_s-Q^1$ ,  $-(CR^aR^{a1})_rC(O)NR^a(CR^aR^{a1})_s-Q^1$ ,  $-(CR^aR^{a1})_rNR^aC(O)(CR^aR^{a1})_s-Q^1$ ,  $-(CR^aR^{a1})_rS(O)_p(CR^aR^{a1})_s-Q^1$ ,  $-(CR^aR^{a1})_rSO_2NR^a(CR^aR^{a1})_s-Q^1$ , or  $-(CR^aR^{a1})_rNR^aSO_2(CR^aR^{a1})_s-Q^1$ ;

25 provided that when n is 0 and  $CR^1R^2$  is  $CHNH_2$ , then  $Z^a$  is other than unsubstituted phenyl;

Q is, independently at each occurrence, H, a  $C_{3-8}$  carbocycle substituted with 0-3  $R^d$ , or a 5-10 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from N, O, and  $S(O)_p$ , and substituted with 0-3  $R^d$ ;

30  $R^{a3}$  is, independently at each occurrence, H,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl, or



-(CH<sub>2</sub>)<sub>r</sub>-3-8 membered carbocyclic or heterocyclic ring consisting of carbon atoms and 0-2 ring heteroatoms selected from N, NR<sup>a2</sup>, O, and S(O)<sub>p</sub>, and substituted with 0-3 R<sup>c1</sup>;

R<sup>c</sup> is, independently at each occurrence, H, OR<sup>a</sup>, Cl, F, Br, =O, CF<sub>3</sub>, CH<sub>2</sub>F, CHF<sub>2</sub>,  
 -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>NR<sup>a</sup>R<sup>a1</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>C(O)R<sup>a1</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>C(O)OR<sup>a1</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>C(O)NR<sup>a</sup>R<sup>a1</sup>,  
 5 -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>NR<sup>a</sup>C(O)R<sup>a1</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>S(O)<sub>p</sub>R<sup>a3</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>SO<sub>2</sub>NR<sup>a</sup>R<sup>a1</sup>,  
 -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>NR<sup>a</sup>SO<sub>2</sub>R<sup>a3</sup>, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, C<sub>3-6</sub> cycloalkyl substituted  
 with 0-1 R<sup>c1</sup>, phenyl substituted with 0-2 R<sup>c1</sup>, or 5-6 membered heterocycle consisting of  
 carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)<sub>p</sub>, and substituted with 0-2  
 R<sup>c1</sup>;

10 alternatively, when two R<sup>c</sup> groups are attached to adjacent carbon atoms, together  
 with the carbon atoms to which they are attached they form a 5-7 membered carbocyclic or  
 heterocyclic ring D substituted with 0-2 R<sup>c1</sup> and consisting of: carbon atoms and 0-2  
 heteroatoms selected from N, O, and S(O)<sub>p</sub>;

R<sup>d</sup> is, independently at each occurrence, C<sub>1-6</sub> alkyl, OR<sup>a</sup>, Cl, F, Br, =O, -NR<sup>a</sup>R<sup>a1</sup>,  
 15 -C(O)R<sup>a</sup>, -C(O)OR<sup>a</sup>, -C(O)NR<sup>a</sup>R<sup>a1</sup>, -S(O)<sub>2</sub>NR<sup>a</sup>R<sup>a1</sup>, -NR<sup>a</sup>S(O)<sub>2</sub>R<sup>a3</sup>, -S(O)<sub>p</sub>R<sup>a3</sup>, CF<sub>3</sub>, or  
 phenyl;

R<sup>5</sup> is, independently at each occurrence, C<sub>1-4</sub> alkyl substituted with 0-2 R<sup>b</sup>, or  
 C<sub>1-4</sub> alkyl substituted with 0-2 R<sup>e</sup>;

r, at each occurrence, is selected from 0, 1, 2, and 3; and

20 s, at each occurrence, is selected from 0, 1, 2, and 3;

provided that:

(a) when R<sup>4</sup>, R<sup>1</sup>, and R<sup>2</sup> are all H, then Z<sup>a</sup> is other than a benzo-fused 5-6 membered  
 heterocycle attached at the 2- or 3-position of the 5-6 membered heterocycle; and

(b) when Z<sup>a</sup> is a benzo-fused 5-6 membered heterocycle attached at the 2- or 3-  
 25 position of the 5-6 membered heterocycle, then at least one of R<sup>1</sup>, R<sup>2</sup>, and R<sup>4</sup> is  
 other than H.

4. A compound according to Claim 3, wherein:

A is -C(O)NHOH;

U is absent or is O, NR<sup>a1</sup>, C(O), CR<sup>a</sup>(OH), C(O)NR<sup>a1</sup>, NR<sup>a1</sup>C(O), S(O)<sub>p</sub>NR<sup>a1</sup>, or NR<sup>a1</sup>S(O)<sub>p</sub>;

Z is phenyl substituted with 0-1 R<sup>b</sup>, or naphthyl substituted with 0-1 R<sup>b</sup>;

Z<sup>a</sup> is phenyl substituted with 1-3 R<sup>c</sup>, naphthyl substituted with 1-3 R<sup>c</sup>, or a  
 5 heterocycle substituted with 1-3 R<sup>c</sup> and selected from furanyl, tetrahydrofuranyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl, isoxazolyl, 4,5-dihydro-isoxazolyl, thienyl, triazolyl, thiadiazolyl, oxadiazolyl, pyridyl, pyrimidinyl, piperazinyl, piperidinyl, pyranyl, pyrazinyl, pyrazolyl, pyridoimidazolyl, pyrrolidinyl, pyrrolyl, indolyl, indolinyl, benzimidazolyl, benzothiazinyl, benzofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl,  
 10 benzisoxazolyl, benzisothiazolyl, quinolinyl, tetrahydroquinolinyl, isoquinolinyl, tetrahydro-isoquinolinyl, indazolyl, isobenzofuranyl, isoindazolyl, isoindolinyl, isoindolyl, methylenedioxyphenyl, quinazolinyl, 1,1-dioxido-2,3-dihydro-4H-1,4-benzothiazin-4-yl, 1,1-dioxido-3,4-dihydro-2H-1-benzothiopyran-4-yl, 3,4-dihydro-2H-chomen-4-yl, 2H-chomen-4-yl, and pyrazolo[1,5-a]pyridinyl;

15 provided that U, Y, Z, and Z<sup>a</sup> do not combine to form a N-N, N-O, O-N, O-O, S(O)<sub>p</sub>-O, O-S(O)<sub>p</sub>, or S(O)<sub>p</sub>-S(O)<sub>p</sub> group;

Q<sup>1</sup> is, independently at each occurrence, H, a C<sub>3-10</sub> carbocycle substituted with 0-5 R<sup>d</sup>, or a 5-10 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)<sub>p</sub>, and substituted with 0-3 R<sup>d</sup>;

20 R<sup>a1</sup> is, independently at each occurrence, H, C<sub>1-6</sub> alkyl, phenyl, or benzyl;

R<sup>a3</sup> is, independently at each occurrence, H, C<sub>1-6</sub> alkyl, phenyl, or benzyl;

R<sup>c</sup> is, independently at each occurrence, H, OR<sup>a</sup>, Cl, F, Br, =O, CF<sub>3</sub>, CH<sub>2</sub>F, CHF<sub>2</sub>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>NR<sup>a</sup>R<sup>a1</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>C(O)R<sup>a1</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>C(O)OR<sup>a1</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>C(O)NR<sup>a</sup>R<sup>a1</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>NR<sup>a</sup>C(O)R<sup>a1</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>S(O)<sub>p</sub>R<sup>a3</sup>, -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>SO<sub>2</sub>NR<sup>a</sup>R<sup>a1</sup>,  
 25 -(CR<sup>a</sup>R<sup>a1</sup>)<sub>r</sub>NR<sup>a</sup>SO<sub>2</sub>R<sup>a3</sup>, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl, C<sub>2-6</sub> alkynyl, phenyl substituted with 0-2 R<sup>c1</sup>, or 5-6 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from N, O, and S(O)<sub>p</sub>, and substituted with 0-2 R<sup>c1</sup>; and

alternatively, when two R<sup>c</sup> groups are attached to adjacent carbon atoms, together with the carbon atoms to which they are attached they form a 5-6 membered carbocyclic or  
 30 heterocyclic ring D substituted with 0-2 R<sup>c1</sup> and consisting of: carbon atoms and 0-2 heteroatoms selected from N, O, and S(O)<sub>p</sub>;

provided that:

- (a) when  $R^4$ ,  $R^1$ , and  $R^2$  are all H, then  $Z^a$  is other than a benzo-fused 5-6 membered heterocycle attached at the 2- or 3-position of the 5-6 membered heterocycle; and
- (b) when  $Z^a$  is a benzo-fused 5-6 membered heterocycle attached at the 2- or 3-position of the 5-6 membered heterocycle, then at least one of  $R^1$ ,  $R^2$ , and  $R^4$  is other than H.

5. A compound according to Claim 4, wherein:

U is absent or is O,  $NR^{a1}$ ,  $C(O)$ ,  $CR^a(OH)$ ,  $C(O)NR^{a1}$ , or  $NR^{a1}C(O)$ ;

10 X is absent or is methylene or butynylene;

Y is absent or is O;

$R^2$  is  $Q^1$ ,  $C_{1-6}$  alkylene- $Q^1$ ,  $C_{2-6}$  alkenylene- $Q^1$ ,  $C_{2-6}$  alkynylene- $Q^1$ ,

$-(CH_2)_rO(CH_2)_s-Q^1$ ,  $-(CH_2)_rNR^a(CH_2)_s-Q^1$ ,  $-(CH_2)_rC(O)(CH_2)_s-Q^1$ ,

$-(CH_2)_rC(O)O(CH_2)_s-Q^1$ ,  $-(CH_2)_rC(O)NR^a(CH_2)_s-Q^1$ ,  $-(CH_2)_rNR^aC(O)(CH_2)_s-Q^1$ ,

15  $-(CH_2)_rS(O)_p(CH_2)_s-Q^1$ ,  $-(CH_2)_rSO_2NR^a(CH_2)_s-Q^1$ , or  $-(CH_2)_rNR^aSO_2(CH_2)_s-Q^1$ ;

provided that when n is 0 and  $CR^1R^2$  is  $CHNH_2$ , then  $Z^a$  is other than unsubstituted phenyl;

Q is, independently at each occurrence, H, a  $C_{3-6}$  carbocycle or a 5-6 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from N, O, and  $S(O)_p$ ;

20  $R^a$  is, independently at each occurrence, H, or  $C_{1-4}$  alkyl;

$R^{a1}$  is, independently at each occurrence, H, or  $C_{1-4}$  alkyl;

$R^{a3}$  is, independently at each occurrence, H,  $C_{1-4}$  alkyl, phenyl, or benzyl;

$R^c$  is, independently at each occurrence,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $OR^a$ ,

Cl, F, Br,  $=O$ ,  $CF_3$ ,  $CH_2F$ ,  $CHF_2$ ,  $NR^aR^{a1}$ ,  $-(CR^aR^{a1})_rC(O)R^{a1}$ ,  $-(CR^aR^{a1})_rC(O)OR^{a1}$ ,

25  $-(CR^aR^{a1})_rC(O)NR^aR^{a1}$ ,  $-(CR^aR^{a1})_rNR^aC(O)R^{a1}$ ,  $-(CR^aR^{a1})_rS(O)_pR^{a3}$ ,

$-(CR^aR^{a1})_rSO_2NR^aR^{a1}$ ,  $-(CR^aR^{a1})_rNR^aSO_2R^{a3}$ , or phenyl; and

alternatively, when two  $R^c$  groups are attached to adjacent carbon atoms, together with the carbon atoms to which they are attached they form a 5-6 membered carbocyclic or heterocyclic ring D substituted with 0-1  $R^{c1}$  and consisting of: carbon atoms and 0-2

30 heteroatoms selected from N, O, and  $S(O)_p$ ;

provided that:

- (a) when  $R^4$ ,  $R^1$ , and  $R^2$  are all H, then  $Z^a$  is other than a benzo-fused 5-6 membered heterocycle attached at the 2- or 3-position of the 5-6 membered heterocycle; and
- (b) when  $Z^a$  is a benzo-fused 5-6 membered heterocycle attached at the 2- or 3-position of the 5-6 membered heterocycle, then at least one of  $R^1$ ,  $R^2$ , and  $R^4$  is other than H.

6. A compound according to Claim 5, wherein:

U is absent or is O,  $NR^{a1}$ , C(O), or  $CR^a(OH)$ ;

Y is absent;

$R^1$  is H or  $C_{1-6}$  alkylene;

provided that when n is 0 and  $CR^1R^2$  is  $CHNH_2$ , then  $Z^a$  is other than unsubstituted phenyl;

$Q^1$  is, independently at each occurrence, H,  $C_{3-6}$  cycloalkyl substituted with 0-1  $R^d$ , phenyl substituted with 0-2  $R^d$ , or a 5-6 membered heterocycle consisting of carbon atoms and 1-4 heteroatoms selected from N, O, and  $S(O)_p$ , and substituted with 0-2  $R^d$ ;

r, at each occurrence, is selected from 0, 1, and 2; and

s, at each occurrence, is selected from 0, 1, and 2;

provided that:

- (a) when  $R^4$ ,  $R^1$ , and  $R^2$  are all H, then  $Z^a$  is other than a benzo-fused 5-6 membered heterocycle attached at the 2- or 3-position of the 5-6 membered heterocycle; and
- (b) when  $Z^a$  is a benzo-fused 5-6 membered heterocycle attached at the 2- or 3-position of the 5-6 membered heterocycle, then at least one of  $R^1$ ,  $R^2$ , and  $R^4$  is other than H.

7. A compound according to Claim 6, wherein:

U is O,  $NR^{a1}$ , or  $CR^a(OH)$ ;

$Z^a$  is phenyl substituted with 1-3  $R^c$ , naphthyl substituted with 1-3  $R^c$ , or a heterocycle substituted with 1-3  $R^c$  and selected from pyridyl, quinoliny, imidazolyl, benzimidazolyl, indolyl, 1,1-dioxido-2,3-dihydro-4H-1,4-benzothiazin-4-yl, 1,1-dioxido-3,4-

dihydro-2*H*-1-benzothiopyran-4-yl, 3,4-dihydro-2*H*-chromen-4-yl, 2*H*-chromen-4-yl, pyrazolyl, and pyrazolo[1,5-*a*]pyridinyl;

$R^b$  is, independently at each occurrence,  $C_{1-6}$  alkyl,  $OR^a$ , Cl, F, Br,  $NR^aR^{a1}$ ,  $C(O)R^a$ ,  $C(O)OR^a$ ,  $C(O)NR^aR^{a1}$ ,  $S(O)_2NR^aR^{a1}$ ,  $NR^aS(O)_2R^{a3}$ ,  $S(O)_pR^{a3}$ , or  $CF_3$ ;

5  $R^c$  is, independently at each occurrence,  $C_{1-6}$  alkyl,  $C_{2-6}$  alkenyl,  $C_{2-6}$  alkynyl,  $OR^a$ , Cl, F, Br, =O,  $NR^aR^{a1}$ ,  $CF_3$ ,  $-(CR^aR^{a1})_rC(O)R^{a1}$ ,  $-(CR^aR^{a1})_rC(O)OR^{a1}$ ,  $-(CR^aR^{a1})_rC(O)NR^aR^{a1}$ ,  $-(CR^aR^{a1})_rNR^aC(O)R^{a1}$ ,  $-(CR^aR^{a1})_rS(O)_pR^{a3}$ ,  $-(CR^aR^{a1})_rSO_2NR^aR^{a1}$ , or  $(CR^aR^{a1})_rNR^aSO_2R^{a3}$ ; and

alternatively, when two  $R^c$  groups are attached to adjacent carbon atoms, together  
10 with the carbon atoms to which they are attached they form a 5-6 membered saturated ring consisting of: carbon atoms and 0-1 heteroatoms selected from N, O, and  $S(O)_p$ ;

provided that:

- (a) when  $R^4$ ,  $R^1$ , and  $R^2$  are all H, then  $Z^a$  is other than a benzo-fused 5-6 membered heterocycle attached at the 2- or 3-position of the 5-6 membered heterocycle; and  
15 (b) when  $Z^a$  is a benzo-fused 5-6 membered heterocycle attached at the 2- or 3-position of the 5-6 membered heterocycle, then at least one of  $R^1$ ,  $R^2$ , and  $R^4$  is other than H.

8. A compound of Claim 1 selected from:

3,N-dihydroxy-2,2-dimethyl-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-  
20 propionamide;

3,N-dihydroxy-2-methyl-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-  
propionamide;

3,N-dihydroxy-2,2-dimethyl-3-[6-(2-methyl-quinolin-4-ylmethoxy)-naphthalen-2-  
yl]-propionamide;

25 3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-propionamide;

4,N-dihydroxy-4-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-butyramide;

2-{hydroxy-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-methyl}-4-methyl-  
pentanoic acid hydroxyamide;

2-benzyl-3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-  
30 propionamide;

- 2-furan-2-ylmethyl-3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-propionamide;
- 3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-2-(tetrahydro-furan-2-ylmethyl)-propionamide;
- 5 3,N-dihydroxy-2-(4-methoxy-benzyl)-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-propionamide;
- 2-(3,5-dimethoxy-benzyl)-3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-propionamide;
- 10 2-benzo[1,3]dioxol-5-ylmethyl-3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-propionamide;
- 3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-2-pyridin-4-ylmethyl-propionamide;
- 3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-2-pyridin-2-ylmethyl-propionamide;
- 15 3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-2-pyridin-3-ylmethyl-propionamide;
- 3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-2-morpholin-4-ylmethyl-propionamide;
- 4-{3-hydroxy-2-hydroxycarbamoyl-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-propyl}-piperidine-1-carboxylic acid *tert*-butyl ester;
- 20 3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-2-piperidin-4-ylmethyl-propionamide;
- 4-{3-hydroxy-2-hydroxycarbamoyl-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-propyl}-piperazine-1-carboxylic acid *tert*-butyl ester;
- 25 3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-2-piperazin-1-ylmethyl-propionamide;
- benzyl-{3-hydroxy-2-hydroxycarbamoyl-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-propyl}-carbamic acid *tert*-butyl ester;
- 2-(benzylamino-methyl)-3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-propionamide;
- 30 {2-hydroxy-1-hydroxycarbamoyl-2-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-ethyl}-methyl-carbamic acid *tert*-butyl ester;
- 3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-2-(tetrahydro-pyran-4-yl)-propionamide;

3,N-dihydroxy-3-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-butyramide;  
N-hydroxy-2-{2-[4-(2-methyl-quinolin-4-ylmethoxy)-phenyl]-tetrahydro-furan-2-  
yl}-acetamide; and  
3,N-dihydroxy-3-(6-methoxy-naphthalen-2-yl)-2,2-dimethyl-propionamide;  
5 or a stereoisomer or a pharmaceutically acceptable salt or prodrug form thereof.

9. A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier  
and a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically  
10 acceptable salt form thereof.

10. A method for treating an inflammatory disorder, comprising: administering to a  
patient in need thereof a therapeutically effective amount of a compound of Claim 1 or a  
15 pharmaceutically acceptable salt form thereof.

11. A method of treating a condition or disease mediated by MMPs and/or TACE, or a  
combination thereof in a mammal, comprising: administering to the mammal in need of  
20 such treatment a therapeutically effective amount of a compound of Claim 1 or a  
pharmaceutically acceptable salt form thereof.

12. A method comprising: administering a compound of Claim 1 or a pharmaceutically  
25 acceptable salt form thereof, in an amount effective to treat a condition or disease mediated  
by MMPs and/or TACE, or a combination thereof.

13. A method of treating according to Claim 12, wherein the disease or condition is  
30 selected from to as acute infection, acute phase response, age related macular degeneration,  
alcoholic liver disease, allergy, allergic asthma, anorexia, aneurism, aortic aneurism,  
asthma, atherosclerosis, atopic dermatitis, autoimmune disease, autoimmune hepatitis,  
Bechet's disease, cachexia, calcium pyrophosphate dihydrate deposition disease,  
cardiovascular effects, chronic fatigue syndrome, chronic obstruction pulmonary disease,

coagulation, congestive heart failure, corneal ulceration, Crohn's disease, enteropathic arthropathy, Felty's syndrome, fever, fibromyalgia syndrome, fibrotic disease, gingivitis, glucocorticoid withdrawal syndrome, gout, graft versus host disease, hemorrhage, HIV infection, hyperoxic alveolar injury, infectious arthritis, inflammation, intermittent

- 5 hydrarthrosis, Lyme disease, meningitis, multiple sclerosis, myasthenia gravis, mycobacterial infection, neovascular glaucoma, osteoarthritis, pelvic inflammatory disease, periodontitis, polymyositis/dermatomyositis, post-ischaemic reperfusion injury, post-radiation asthenia, psoriasis, psoriatic arthritis, pulmonary emphysema, pyoderma gangrenosum, relapsing polychondritis, Reiter's syndrome, rheumatic fever, rheumatoid
- 10 arthritis, sarcoidosis, scleroderma, sepsis syndrome, Still's disease, shock, Sjogren's syndrome, skin inflammatory diseases, solid tumor growth and tumor invasion by secondary metastases, spondylitis, stroke, systemic lupus erythematosus, ulcerative colitis, uveitis, vasculitis, and Wegener's granulomatosis.

15

14. A method for treating inflammatory disorders, comprising: administering, to a host in need of such treatment, a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt form thereof, in combination with one or more additional anti-inflammatory agents selected from selective COX-2 inhibitors, TNF- $\alpha$  inhibitors and
- 20 TNF- $\alpha$  antibody or protein sequestration agents.

15. An article of manufacture, comprising:

- (a) a first container;
- 25 (b) a pharmaceutical composition located within the first container, wherein the composition, comprises: a first therapeutic agent, comprising: a compound of Claim 1 or a pharmaceutically acceptable salt form thereof; and,
- (c) a package insert stating that the pharmaceutical composition can be used for the treatment of an inflammatory disorder.

30

16. An article of manufacture according to Claim 18, further comprising:
- (d) a second container;



wherein components (a) and (b) are located within the second container and component (c) is located within or outside of the second container.

5     17.     An article of manufacture, comprising:

          (a) a first container;

          (b) a pharmaceutical composition located within the first container, wherein the composition, comprises: a first therapeutic agent, comprising: a compound of Claim 1, or a pharmaceutically acceptable salt form thereof; and,

10           (c) a package insert stating that the pharmaceutical composition can be used in combination with a second therapeutic agent to treat an inflammatory disorder.

18.     An article of manufacture according to Claim 20, further comprising:

15           (d) a second container;

wherein components (a) and (b) are located within the second container and component (c) is located within or outside of the second container.